News

Involved Max Perutz Labs group leaders, from top left to bottom right: Christopher Campbell, Alexander Dammermann, Verena Jantsch, Franz Klein, Joao Matos, Peter Schlögelhofer

The Austrian Science Fund (FWF) has awarded a special research programme (SFB) grant to six research groups from the Max Perutz Labs and scientists…

20 Jan'22

Valneva nnounced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva’s inactivated COVID-19…

17 Jan'22

B cells proliferate, differentiate, and mutate in temporary cell clusters called germinal centres. In a process known as the germinal centre reaction,…

06 Jan'22

Valneva confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19…

23 Dec'21

The latest call of the Vienna Science and Technology Fund for projects in the field of chemical biology has resulted into a great success for the IMP.…

11 Dec'21

CEBINA GmbH informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major…

08 Dec'21

A woman on the left and a man on the right look and smile at the camera. Wooden background.

In an exceptional double-success for the IMP, Anna Obenauf and Clemens Plaschka were selected by the European Molecular Biology Organization (EMBO) to…

03 Dec'21

Sanofi announced that it has entered into an agreement to acquire Origimm Biotechnology GmbH.

03 Dec'21

In October 2021, BioNTech expanded its infectious disease portfolio capabilities by acquiring PhagoMed Biopharma GmbH, an Austrian biotechnology…

02 Dec'21

The development of human blastoids, human embryo models at IMBA, paves the way for improving in vitro fertilization success rate and new non-hormonal,…

02 Dec'21

Valneva confirmed that the European Medicines Agency (EMA) has started a rolling review of VLA2001, its whole-virus inactivated, adjuvanted COVID-19…

30 Nov'21

Valneva and IDT Biologika today announced their collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001.

Read…

New funding for meiosis research

Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant

Bhlhe40, a molecular gatekeeper that prevents the formation of lymphomas

Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001

Tim Clausen and collaborators secure two prestigious grants

CEBINA reports broad anti-viral potency of azelastine has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant

Anna Obenauf and Clemens Plaschka elected EMBO Young Investigators

Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy

PhagoMed becomes BioNTech R&D (Austria)

Breakthrough research on human blastoids and impact on IVF and contraception

Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001

Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001